- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Syndax Pharmaceuticals Inc (SNDX)
15.67
+0.28(+1.79%)
Real-time Data·
Fair Value
An estimate of a Syndax Pharmaceuticals's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.37
15.89
52 wk Range
8.58
22.50
SNDX Financial Summary
A brief financial summary of Syndax Pharmaceuticals Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.
Key Ratios
Statements Highlights
| Period Ending: | 2015 31/12 | 2016 31/12 | 2017 31/12 | 2018 31/12 | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1.52 | 139.71 | - | - | 23.68 | |
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1.52 | 139.71 | -118.5 | -163.03 | -218.79 | |
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -71.42 | 26.22 | -151.76 | -229.95 | -339.67 | |
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -73.16 | 24.93 | -149.34 | -209.36 | -318.76 | |
Total Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 300.61 | 449.66 | 497.24 | 612.88 | 724.82 | |
Total Current Liabilities | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 18.87 | 20.68 | 29.07 | 58.1 | 103.55 | |
Total Equity | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 252.19 | 408.37 | 467.45 | 554.2 | 288.12 | |
Levered Free Cash Flow | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -38.44 | 32.03 | -76.27 | -82.37 | -155.26 | |
Cash from Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -71.26 | 29.13 | -133.68 | -160.6 | -274.9 | |
Cash from Investing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -142.53 | -40.87 | -186.19 | 117.61 | -219.78 | |
Cash from Financing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 304.42 | 118.46 | 172.25 | 264.13 | 353.37 | |
Net Change in Cash | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 90.63 | 106.72 | -147.61 | 221.14 | -141.31 | |
* In Millions of USD (except for per share items)
Analyst Ratings
12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 36.36
(+132.06% Upside)
FAQ
What were Syndax Pharmaceuticals's earnings for the latest quarter?
The Syndax Pharmaceuticals EPS (TTM) is -3.89. Syndax Pharmaceuticals reported sales of 37.96, net income of -71.85, and EPS of -0.83 for the latest quarter.
What was Syndax Pharmaceuticals's net income for the latest quarter?
Syndax Pharmaceuticals's net income for the latest quarter was -71.85.
How did Syndax Pharmaceuticals's performance compare year-over-year in the latest quarter?
The company's revenue moved from 20.04 in the previous quarter to 37.96 in the latest quarter, and net income moved from -84.85 to -71.85 compared to the previous quarter.
What is Syndax Pharmaceuticals's net profit margin on a TTM basis?
Syndax Pharmaceuticals's trailing twelve months (TTM) net profit margin is -1,346.11%.
How does Syndax Pharmaceuticals's debt to equity ratio compare to industry standards?
Syndax Pharmaceuticals's total debt-to-equity ratio is 219.49%.
What is Syndax Pharmaceuticals's return on investment on a TTM basis?
Syndax Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is -113.22%.
Did Syndax Pharmaceuticals gain or lose cash last quarter?
In the latest quarter, Syndax Pharmaceuticals's net change in cash was -45.36 million.
What were Syndax Pharmaceuticals's total assets and liabilities in the latest quarter?
As of the latest quarter, Syndax Pharmaceuticals reported total assets of 596.15 million and total liabilities of 112.99 million.
How has Syndax Pharmaceuticals's total revenue grown this year?
Syndax Pharmaceuticals's total revenue was 20.04 in the previous quarter and 37.96 in the latest quarter.
What is Syndax Pharmaceuticals's gross margin on a TTM basis?
Syndax Pharmaceuticals's trailing twelve months (TTM) gross margin is -237.92%.
What was Syndax Pharmaceuticals's revenue per share for the latest quarter?
Syndax Pharmaceuticals's revenue per share for the latest quarter was 3.07.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.